Literature DB >> 17596369

Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases.

Kenneth S Thomson1, Nancy E Cornish, Seong G Hong, Kim Hemrick, Christian Herdt, Ellen S Moland.   

Abstract

The VITEK 2 and Phoenix extended-spectrum beta-lactamase (ESBL) detection systems, which comprise confirmatory tests and expert systems, were evaluated for their ability to discriminate between 102 well-characterized strains of ESBL-positive or -negative Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. At least 38 distinct ESBLs were included. The strains were chosen to include some known to cause false-positive and false-negative CLSI ESBL confirmatory test results. Therefore, enzyme characterizations, rather than CLSI tests, were the reference methods for the Phoenix and VITEK 2 evaluations. A third arm of the study was conducted with the Phoenix test using two normally inactive expert rules intended to enhance ESBL detection, in addition to using the currently available software. The Phoenix ESBL confirmatory test and unmodified expert system exhibited 96% sensitivity and 81% specificity for ESBL detection. Activation of the two additional rules increased sensitivity to 99% but reduced the specificity to 58%. The VITEK 2 ESBL confirmatory test exhibited 91% sensitivity, which was reduced to 89% sensitivity by its expert system, while its specificity was 85%. Many of the expert system interpretations of both instruments were helpful, but some were suboptimal. The VITEK 2 expert system was potentially more frustrating because it provided more inconclusive interpretations of the results. Considering the high degree of diagnostic difficulty posed by the strains, both ESBL confirmatory tests were highly sensitive. The expert systems of both instruments require modification to update and enhance their utility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596369      PMCID: PMC1951213          DOI: 10.1128/JCM.00776-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.

Authors:  Irith Wiegand; Heinrich K Geiss; Dietrich Mack; Enno Stürenburg; Harald Seifert
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Teresa Spanu; Daniela Ciccaglione; Lucio Romano; Barbara Fiori; Giuseppe Nicoletti; Stefania Zanetti; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.

Authors:  K S Thomson; C C Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 6.  Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support.

Authors:  L Poirel; P Nordmann
Journal:  Curr Pharm Biotechnol       Date:  2002-06       Impact factor: 2.837

7.  Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates.

Authors:  Ellen Smith Moland; Nancy D Hanson; Vicki L Herrera; Jennifer A Black; Thomas J Lockhart; Ashfaque Hossain; Judith A Johnson; Richard V Goering; Kenneth S Thomson
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

8.  Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates.

Authors:  Enno Stürenburg; Ingo Sobottka; Heinz-Hubert Feucht; Dietrich Mack; Rainer Laufs
Journal:  Diagn Microbiol Infect Dis       Date:  2003-01       Impact factor: 2.803

9.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Authors:  Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

Review 10.  Controversies about extended-spectrum and AmpC beta-lactamases.

Authors:  K S Thomson
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  18 in total

1.  Evaluation of the VITEK 2 AST-N111 card for detection of extended-spectrum beta-lactamases (ESBLs) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca compared to ESBL Etests and combination disk methods.

Authors:  G Valenza; S Müller; C Schmitt; D Turnwald; T-T Lam; M Frosch; M Abele-Horn; Y Pfeifer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-27       Impact factor: 3.267

2.  Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum beta-lactamase, AmpC and KPC producers.

Authors:  Mark A Fisher; Paul D Stamper; Kristine M Hujer; Zachary Love; Ann Croft; Samuel Cohen; Robert A Bonomo; Karen C Carroll; Cathy A Petti
Journal:  J Med Microbiol       Date:  2009-06       Impact factor: 2.472

3.  Extended-spectrum Beta-lactamase detection with different panels for automated susceptibility testing and with a chromogenic medium.

Authors:  J Färber; K-A Moder; F Layer; I Tammer; W König; B König
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

4.  Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae.

Authors:  Hélène Garrec; Laurence Drieux-Rouzet; Jean-Louis Golmard; Vincent Jarlier; Jérôme Robert
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

Review 5.  Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors:  Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

Review 6.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 7.  New and developing diagnostic technologies for urinary tract infections.

Authors:  Michael Davenport; Kathleen E Mach; Linda M Dairiki Shortliffe; Niaz Banaei; Tza-Huei Wang; Joseph C Liao
Journal:  Nat Rev Urol       Date:  2017-03-01       Impact factor: 14.432

8.  Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens.

Authors:  Samuel A Shelburne; Jiwoong Kim; Jose M Munita; Pranoti Sahasrabhojane; Ryan K Shields; Ellen G Press; Xiqi Li; Cesar A Arias; Brandi Cantarel; Ying Jiang; Min S Kim; Samuel L Aitken; David E Greenberg
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

9.  Evaluation of the capability of the VITEK 2 system to detect extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates, in particular with the coproduction of AmpC enzymes.

Authors:  H M Chen; J J Wu; P F Tsai; J Y Wann; J J Yan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-13       Impact factor: 3.267

10.  Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.

Authors:  Mario Tumbarello; Michela Sali; Enrico Maria Trecarichi; Fiammetta Leone; Marianna Rossi; Barbara Fiori; Gennaro De Pascale; Tiziana D'Inzeo; Maurizio Sanguinetti; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.